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In August 2010, the World Health Organization and the Korea Food & Drug Administration jointly
organized the ﬁrst implementation workshop of WHO guidelines on evaluating similar biotherapeutic
products (SBPs) at the global level. The objective of the Workshop was to facilitate implementation of the
newly adopted WHO Guidelines into the practice of national regulatory authorities (NRAs). WHO
Guidelines were recognized by the workshop participants as a tool for harmonizing regulatory
requirements worldwide. By reviewing and practicing several case studies, better understanding and
consensus on the principles of clinical trial designs were reached. However, variations in terms of the
national requirements for quality, safety and efﬁcacy of these products revealed diversity in the regu-
latory expectations in different countries and regions. In addition, lack of terminology for the products
developed as copy products (so called "me too" products) with a partial comparability to an RBP, led to
a great diversity in evaluating as well as naming these products. The workshop participants proposed the
following actions: a) NRAs should make efforts to build their capacities for regulation of SBPs; b) WHO
should revise WHO Guidelines for assuring the quality of products prepared by recombinant DNA
technology (WHO TRS 814) and continue monitoring progress with the implementation of the Guide-
lines on evaluating SBPs. Publication of the outcome of the Workshop was recognized as another action
that WHO should coordinate.
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Publisher permission for the reproduction of this article.: þ41 22 791 4971.
O/ KFDA workshop on implementing WHO Guidelines on evaluating similar biotherapeutic products. List of partici-
elangor, Malaysia; Dr Chiyoung Ahn, Korea Food and Drug Administration (KFDA), Seoul, Republic of Korea; Dr Teruyo
okyo, Japan; Anna-Maija Autere, Roche Products Limited, Welwyn Garden City, UK, representative of the International
ciations (IFPMA); Dr Adnan Badwan, Jordanian Pharmaceutical Manufacturing Co PLC, Naor, Jordan, representative of
als and Medical Appliances (AUPAM); Dr Alexander Berghout, Sandoz Biopharmaceutical Development, Holzkirchen,
dicines Association (EGA); Dr Laura Gomes Castanheira, National Health Surveillance Agency (ANVISA), Brazil; Dr Xu
eijing, People’s Republic of China, representative of Chinese manufacturers; Dr Keum S. Choi, KFDA, Seoul, Republic of
a; MD Mark P. Fletcher, Consultant to Pﬁzer, Charlottesville, USA, representative of the International Federation of
A); Dr Naser Hadavand, Food & Drug Organization, Ministry of Health and Medical Education, Tehran, Iran; Rania D.
an, Jordan; Dr Hans-Karl Heim, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany; Dr Hyi-Jeong
sentative of Korean manufacturers; Dr Jeewon Joung, KFDA, Seoul, Republic of Korea; Dr Agnes Klein, Health Canada,
tzerland, Representative of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA); Dr
Mediterranean, Cairo Egypt; Dr Cheng Gang Liang, National Institute for the Control of Pharmaceutical & Biological
hui Luo, States Food and Drug Administration (SFDA), Beijing, People’s Republic of China; Dr Hemant Malhotra, SMS
jue, Health Canada, Ottawa, Canada; Mrs Yanet Hechavarria Nunez, Centro para el Control Estatal de la Calidad de los
; Dr Suenie Park, KFDA, Seoul, Republic of Korea; Dr Younjoo Park, KFDA, Seoul, Republic of Korea; Dr Maria Luz Pombo,
Health Organization, (PAHO) Biological Vaccines Ofﬁce, Washington, United States of America; Dr Martin Schiestl,
the International Generic Pharmaceutical Alliance (IGPA); Dr Jinho Shin, FCH/IVB/QSS, WHO, Geneva, Switzerland; Dr
okyung Suh, KFDA, Seoul, Republic of Korea; Dr Kai Tong Tam, Health Science Authority, Singapore; Mrs Prapassorn
y of Public Health, Nonthaburi, Thailand; Dr. Kriang Tungsanga, Chulalongkorn University, Bangkok, Thailand; Cornelia
e of the European Generic medicines Association (EGA); Dr Zulane da Silva Tavares Veiga, Bio-Manguinhos/Fiocruz,
sentative of the Developing Country Vaccine Manufacturing Network (DCVMN); Ms Jalene Poh Wang Woon, Health
i, National Institute of Health Sciences, Tokyo, Japan.
ll rights reserved. The World Health Organization has granted the Publisher permission for the reproduction of this article.
M. Wadhwa et al. / Biologicals 39 (2011) 349e3573501. Introduction
Dr Yun-Hong Noh, the commissioner of Korea Food and Drug
Administration (KFDA) opened the workshop with a welcome
address which highlighted the importance of biosimilar medicines
in the global market. On behalf of WHO, Dr Ivana Knezevic (WHO,
IVB, QSS) welcomed all the participants, chairperson and rappor-
teurs and explained that the objective of the workshop was to
review the current situation with the regulation of biosimilar
products and to deﬁne next steps towards better access to bio-
therapeutics of assured quality. Focus of the workshop was the
application of the principles deﬁned in the WHO Guidelines on
Evaluation of Similar Biotherapeutic Products (SBPs) into regula-
tory and manufacturers’ practices worldwide [1]. She added that
the outcome of the workshop would be reported to the Expert
Committee on Biological Standardization (ECBS) in October 2010
and to the International Conference of Drug Regulatory Authorities
(ICDRA) in November 2010 for further considerations and advice.
Dr Knezevic invited all participants to share their experience and to
contribute to the discussion as well as to the preparation of
a publication reﬂecting the proceedings and outcome of the
workshop afterwards.
The workshop organized jointly by the WHO and KFDA was
attended by participants from regulatory agencies from various
countries, clinical and scientiﬁc experts and representatives from
industry. Dr Elwyn Grifﬁths (Health Canada, Canada) was appoin-
ted the chairperson and Dr Robin Thorpe (NIBSC, UK) and DrMeenu
Wadhwa (NIBSC, UK) served as rapporteurs.
Following a self-introduction by all participants, the chairperson
commented brieﬂy on the intense interest from governments
worldwide in biosimilar products and thanked the WHO team for
their resilience in forging ahead amid much controversy with the
very difﬁcult task of producing the Guidelines on SBPs and their
adoption ﬁnally in October 2009. He mentioned that the guidelines
enabled harmonization of key principles for evaluation of quality,
safety and efﬁcacy of biosimilar products and themain objective for
the WHO team, therefore, was to facilitate global implementation
of the guidelines and to identify any problems or issues that the
various regions are facing with implementing the principles out-
lined in the guidelines.
Dr Ivana Knezevic brieﬂy described the WHO Biological stand-
ardisation program which includes provision of both written
(guidelines and recommendations for production, quality control
and evaluation of biologicals) and measurement standards (Inter-
national Standards and Reference Preparations); the latter served as
physical potency standards for calibration of biologicals worldwide.
Following a brief overviewof the backgroundon the development of
WHO guidelines on SBPs (mandated by the ICDRA, 2006 [2] and the
ECBS, 2007) and the consultations which enabled the formulation
and theﬁnal adoption of theWHOSBPguidelines by the ECBS (at the
60th meeting) [3], she emphasized that the key principles for eval-
uation of SBPs highlighted in the guideline provide a basis for
different regulatory authorities to set national requirements for
licensure of these products. She explained the scope and important
key deﬁnitions such as SBP, reference biotherapeutic products (RBP)
and the importance of using appropriate terminology. The guideline
advocates the principle of a step-wise comparability approach for
SBP evaluation - similarity of the SBP to RBP in terms of quality is
a prerequisite for reduction of non-clinical and clinical data required
for approval. Additionally, comparative efﬁcacy data showing
equivalence or non-inferiority in adequately powered, randomized
trials and comparative safety data are required to demonstrate
biosimilarity of the SBP with RBP, which if shown may allow
extrapolation toother indicationsof theRBP for theSBP. Theneed for
pharmacovigilance and the use of appropriate method(s) foridentiﬁcation of the administered product, along with post-
marketing commitments and risk minimization strategies were
stressed. She concluded that for an effective regulatory oversight of
SBPs in various countries, the involvement of various stakeholders
(e.g. industry, regulators, WHO) is critical to ensure implementation
of guidelines.While some progress towards implementation and/or
development of guidance documents in various countries had been
made, there were many challenges which need to be addressed for
global harmonization of the regulatory framework for licensure of
biotherapeutics.
Dr Jinho Shin (WHO) gave an overview of WHO’s International
Nonproprietary Name (INN) policy including its naming schemes
and use with speciﬁc examples for a number of biotherapeutics.
The INN facilitates the identiﬁcation of active pharmaceutical
substances in a medicinal product and is intended for use in
pharmacopoeias, labelling, product information, advertising, drug
regulation and scientiﬁc literature, and as a basis for product
names, e.g. for generics. For generic drugs, the same INN as the
innovator product is assigned. In 2006, an informal WHO consul-
tation on INN policy for biosimilars discussed how INNs should be
assigned to biosimilar products and concluded that INNs for all
biological products should be based on molecular characteristics
and pharmacological class and not on regulatory route used for
licensure [4]. There should be no change in policy and no distinctive
INN designation for biosimilar products and decisions regarding
product interchangeability should be based on appropriate scien-
tiﬁc and clinical data as decided by the national regulatory
authority, not on INNs.
2. Updating region/country situations on evaluating SBPs
Dr Maria Luz Pombo (WHO, Pan American Health Organization,
PAHO region) mentioned that a previous survey (2008) conducted
in the PAHO region had shown that most of the Latin American and
Caribbean countries had regulations for biological products [5].
Some countries have licensed non-innovator copy products but no
clear deﬁnition or process for approval is often in place. Based on
the interest shown by the PAHO countries for harmonized docu-
ments and mechanisms for licensing biotechnology products,
a technical working group on biotechnology products with partic-
ipants from various countries had been established. This group
aims to promote information exchange among regulatory author-
ities in terms of regulations, identify guidelines and issues and
develop tools and training programs for harmonization of effective
regulatory oversight of biotechnology products within the region.
Dr Adnan Badwan (AUPAM, Jordan) provided an overview of the
diverse activities of Arab Union of the Manufacturers of Pharma-
ceuticals and Medical Appliances (AUPAM) and the situation and
practices in the Arab region in evaluating SBPs. He mentioned that
biotherapeutic products, including biosimilars, are imported from
several countries; a majority of these are repackaged imported
products. Two licensed non-innovator products, erythropoietin
from Argentina and insulin produced by a regional manufacturer
are available in Egypt. More recently, biotherapeutic product
manufacturing has been initiated within the region but the
manufacturing is not well-controlled and uniﬁed as products are
manufactured at different sites depending on the development
stage and then formulated in yet another site/country. The reasons
for this are the lack of expertise in assessment of biotechnology
products including biosimilars and inexperience with regulatory
processes. Consequently, there is a need for WHO intervention in
increasing training for product testing of SBPs and awareness of
regulation in the region.
Dr HemantMalhotra (clinician, Jaipur, India) mentioned that the
lower costs of ‘copy’ products had increased access of these
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marketed copy products; these products are also available in less
regulated countries but the approval process for these is not clear.
Quality, non-clinical and clinical evaluations of the product are
conducted as per the national regulations but they are not done in
a comparative manner. More likely, non-comparative clinical trial
data showing similarity to published data on the reference product
were used for approval. Guidance for Industry for biological prod-
ucts has become available since 2009, but signiﬁcant resource
constraints (skill shortage, training) mean that signiﬁcant progress
towards implementation of theWHO guideline in the near future is
unlikely.
Ms. Jalene Poh (HSA, Singapore) explained that Singapore’s
biosimilar guidance is mainly based on EU’s biosimilar guidelines
with consideration of Singapore’s local regulatory environment
[6e9]. The prerequisite for submission of a biosimilar product is
that it has to be evaluated and approved as a biosimilar product by
at least one of HSA’s reference agencies (i.e. US FDA, Health Canada,
EMA, or Therapeutic Goods Administration). A complete quality,
non-clinical and clinical data package demonstrating comparability
between the biosimilar and reference product is needed for
submission. The conditions of use of the biosimilar product are
those deﬁned for the reference product registered in Singapore
(and not for other indications which may be approved elsewhere).
Interchangeability is allowed but not substitutability and the
product leaﬂet requires a warning statement regarding substitut-
ability. To date, there is one approved biosimilar Growth Hormone
product, SciTropin A (Omnitrope, Sandoz) based on the reference
product, Genotropin (Pﬁzer).
3. Exchanging the experiences with comparability studies/
RBPs
Dr Rania D. Hadaddin (JFDA, Jordan) provided a brief overview
of the regulatory framework for registration of biosimilar products
and EMA speciﬁc guidelines until speciﬁc guidelines for registra-
tion of biological and biosimilar products are release. Prior to 2006,
few biosimilars were registered using the process applied to
generic drugs. Licensing of RBP in Jordan is not a prerequisite for
using RBP in the comparability studies and the ﬁrst product
registered internationally with a particular active ingredient is
considered as the RBP. In the example that Dr Haddadin presented,
the originator was licensed in USA. In the same example, she dis-
cussed the clinical comparability studies submitted for approval. A
post-marketing surveillance study is requested after a biosimilar
product is authorized.
Dr Younjoo Park (KFDA, Republic of Korea) mentioned that
guidance for biosimilar products, developed in July 2009 [10],
follow the principles for evaluation of biosimilar products as
described in WHO and EMA Guidelines. She also presented an
abbreviated pathway which only requires the demonstration of
clinical comparability to RBP. In the latter approach, there is no
comparison with the RBP in terms of quality and approval is based
on a full quality assessment of the product followed by a reduced
data package for non-clinical studies. Both pathways co-exist, but
only the products which are approved through the biosimilar
pathway described in their guidelines can be called ’biosimilars’. No
biosimilars have been approved.
4. Challenges raised by reviewers
Dr Hans-Karl Heim (BfArM, Germany) brieﬂy described the EU
biosimilar approach and the requirements of the product speciﬁc
guidelines, which form the basis for the non-clinical evaluation for
biosimilars [9,11e14]. Study design should be sufﬁcient to detectdifferences in pharmacological and toxicological response between
the SBP and reference medicinal product and not just the response
per se, and is tailored to the speciﬁc product on a case-by-case basis,
with justiﬁcation. He reviewed the non-clinical study data
submitted for approval of some biosimilar products (e.g. growth
hormone, G-CSF, erythropoietin) currently licensed in EU and
commented that, in some cases, there are deviations in the studies
from the guidelines as guidelines were not available when the
products were in development. However, future applications for
biosimilars are expected to adhere closely to the approaches rec-
ommended in the guidelines.
Dr Cheng Gang Liang (NICPBP, China) stated that there is neither
deﬁnition nor speciﬁc regulations for biosimilars. Products are
registered according to the national drug registration regulations.
Several marketed products are available e.g. insulin and growth
hormone approved using a stand-alone approach which requires
a comprehensive evaluation of product quality but reduced
preclinical data (not comparatively assured). In practice, principles
of WHO SBP guidelines are partly followed and the regulatory
authorities are working towards strengthening of documentary
requirements and guidelines for SBPs.
Dr Laura Gomes Castanheira (ANVISA, Brazil) stated that the
WHO and Canadian guidelines [15] were being used as the basis
for developing regulations which were being implemented in
Brazil in the following month. An RBP licensed and marketed in
Brazil was preferred but if not available, an RBP from the same
manufacturing site using the same production method (as the
marketed product in Brazil) was allowed. Two pathways are
deﬁned in the regulatory framework e the biosimilar and alter-
native (abbreviated) pathway since manufacturers are reluctant to
perform comparative clinical trials because of the high costs
involved. She presented a case study which reviewed non-clinical
data of a similar G-CSF product and included both non-
comparative and comparative studies. However, the limited
comparative studies presented demonstrated that there were no
detectable and signiﬁcant differences between the SBP and the
RBP and were adequate for progressing with clinical development.
Dr Agnes Klein (Health Canada, Canada) gave an overview of the
challenges and experiences of the Canadian regulators during
approval of their ﬁrst biosimilar, Omnitrope (GH). The terminology
adopted for SBPs which are considered as ‘New Drugs’ in Canada is
Subsequent Entry Biologics (SEB). The regulatory framework and
guidance issued for SEBs/SBPs by Health Canada [15] is based on
a balanced, science-based and rational approach to ensure that the
products approved are of high quality, safe and are effective. For
comparability, the use of an RBP from a well-regulated jurisdiction
is allowed. The principles outlined in the guidance were evaluated
during the approval of Omnitrope using Genotropin as the
comparator which although approved is not marketed in Canada.
Despite initial rejection/deﬁciencies (reasons included non-
marketing of Genotropin, requests for indications not approved
for Genotropin and the different standards used for growth
assessment in clinical studies), Omnitrope was ﬁnally approved
with post-marketing commitments being required. The process
allowed ﬂexibility and thorough evaluation of the product from the
comparability perspective that was critical to the ﬁnal outcome.
5. Better understanding of the principles of clinical
evaluation
Dr Catherine Njue (Health Canada, Canada) explained the
statistical issues related to equivalence and non-inferiority trials. As
per theWHO SBP guidelines, equivalence or non-inferiority studies
may be acceptable for comparing the efﬁcacy and safety of the SBP
with the RBP [1]. While equivalence trials are preferred, non-
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critical need for a thorough evaluation of all comparative data
generated to ensure similarity between the SBP and the RBP prior
to initiating a clinical study was emphasized. The protocol of the
trial should explicitly deﬁne the purpose of the trial, e.g. demon-
stration of equivalence or non-inferiority of the SBP to the RBP. The
choice of the equivalence or non-inferiority margin must be clearly
justiﬁed. Importantly, equivalence and non-inferiority trials require
different formulae for power and sample size calculations, and so
the appropriate set of formulae should be used in each setting.
Inadequately powered studies are unethical and should not be
conducted. Only data obtained from robust equivalence or non-
inferiority trials is capable of determining clinical similarity
between the SBP and the RBP.
Dr. Alexander Berghout (Sandoz, EGA) provided an overview of
the clinical data (PK and PD studies; efﬁcacy and safety studies)
that were submitted to the EMA for licensing of the three Sandoz
biosimilar products currentlymarketed; these include Omnitrope
(Growth hormone, RBP - Genotropin), Binocrit (Erythropoietin
a, RBP - Eprex) and Zarzio (G-CSF, RBP - Neupogen). The clinical
studies conﬁrmed similarity of the SBPs with their respective RBPs.
He pointed out that clinical comparability studies should prefer-
ably use the most sensitivemodel to detect differences, if any exist.
As an example he presented the effects seen in the comparison of
Zarzio with Neupogen in healthy volunteers which represents
a very sensitive model especially at low doses due to the complex
receptor-mediated drug disposition of ﬁlgrastim and the higher
number of G-CSF receptors and a more responsive bone marrow
than in neutropenia patients undergoing cytotoxic chemotherapy.
Small differences in PK were detected due to unintentional small
differences in the administered dose without any detectable
differences in PD response. He concluded that SBPs have been
extensively characterized at the physicochemical and biological
level to demonstrate similarity. If in addition PK/PD comparability
has been proven, it may be appropriate to use non-inferiority
designs to demonstrate clinically relevant comparability, as it can
be expected that the SBP will be neither inferior nor superior to
the RBP.
Dr Teruyo Arato (Pharmaceuticals and Medical Devices Agency,
Japan) mentioned that after the Japanese guideline became avail-
able [16], two follow-on biologics (Japanese terminology), Soma-
tropin and Epoietin alpha, have been approved and more are in
development. While the principles are similar between the EMA,
Canada, WHO and Japanese guidelines, there are some differences
in the scope (Low-molecular weight heparin is excluded from
Japanese guideline) and also in terms of regulatory requirements
pertaining to the RBP, stability testing, safety of process-related
impurities and other criteria. She mentioned that for Epoietin
Alfa BS “JCR” (JCR is a company namewhich should be positioned at
the end of brand name of biosimilars according to Japanese noti-
ﬁcation), the non-clinical and clinical data required was different
from those of erythropoietin biosimilar products approved in EU. In
Japan, a system for naming of follow-on biologics has also been
adopted such that for the INN of the follow-on biologic, ‘BS’ (bio-
similar) is sufﬁxed to the INN of the original biologic at approval
along with the unique brand name (which includes dosage form,
strengths and company name e.g. Epoietin Alfa BS Inj 750 “JCR”) for
product identiﬁcation.
6. Case study on clinical efﬁcacy
Dr Mark P. Fletcher (IFPMA) led an interactive discussion among
participants on key issues in clinical trial designs for showing
similarity of an SBP with an RBP as discussed in the WHO SBP
guidelines. A case study based on a hypothetical product waspresented as a model to facilitate discussion on sample sizes and
comparability margins for both an equivalence and a non-
inferiority study design approach. In this context, the interpreta-
tion of possible clinical outcomes (e.g. data supporting approval or
non-approval or being inconclusive) using these two clinical trial
designs was explained. Ensuring choice of sensitive markers/end-
points for safety and efﬁcacy is a key consideration, particularly if
a reduced clinical data package is intended for approval. Equiva-
lence is the most suitable design for conﬁrming that the SBP is
similar to the RBP although non-inferiority designs may also be
considered if appropriately justiﬁed. The need for a case-by-case
approach was highlighted. More importantly, demonstration of
a similar safety proﬁle of the SBP and RBP requires signiﬁcantly
more data (more subjects, long duration) on the safety aspects than
that required for showing similar efﬁcacy.
7. Regulators and manufacturer’s perspectives on
implementation of WHO guidelines
Dr Hye-Na Kang (WHO) presented an update on the regulations
governing biologicals including SBPs and the current situation
regarding implementation of theWHO SBP guidelines. As expected,
the regulations and terminologies used for biotherapeutic products
including SBPs are diverse. Some countries have the same regula-
tions for both drugs and biologicals while others have additional
regulations for biologicals. Progress with development and imple-
mentation of SBP guidelines differs at the regional and country
level. While some countries have developed SBP guidelines and the
principles for acceptance of RBPs from different jurisdictions,
others are clearly lagging behind. This is because some countries
lack the expertise needed for assessment of biotherapeutics (from
quality to clinical data evaluation). Based on the different level of
expertise in the regulatory authorities, the need for training was
highlighted as a major issue for many countries.
Dr Martin Schiestl (Sandoz, IGPA) emphasized the WHO SBP
principles underlying the manufacture of SBPs which are system-
atically engineered using optimized processes tomatch the RBP and
then evaluated in a comparative manner using a step-wise
approach. He cautioned on the use of ‘biosimilar’ terminology (if
products are not comparable in quality aspects) and route for
productswhich do not complywith the biosimilarity concept. Using
the example of Reditux (Shantha Biotech, India) which has the same
amino acid sequence as the originator, Rituxan (anti-CD20 mono-
clonal antibody, Hoffman La Roche, Switzerland), he highlighted
many differences at the quality level between the two products
which clearly demonstrated that Reditux is not a biosimilar of Rit-
uxan and may therefore have a very different safety and efﬁcacy
proﬁle. Currently, SBP manufacturers are developing monoclonal
antibodies (Mab) since patents for many of these are likely to expire
soon. Setting criteria for biosimilarity for these potential SBPs is
based on the variability observed with the original reference Mab
product. Thismaybe inpart due to changes in the product over time.
The experience gained by the regulatory agencies over time with
regard to the assessment of those process changes of the originator
molecule may thus be utilized for the evaluation of biosimilarity.
Dr Hyi-Jeong Ji (LG Life Sciences, Ltd., Republic of Korea) pre-
sented the practical points to consider from the Korean industry’s
perspective in implementing the development of SBPs according to
the WHO guidelines. She emphasized WHO’s role in harmonizing
regulatory oversight and facilitating development of the experience
and expertise of NRAs in evaluating SBPs. The establishment of the
criteria for regulatory evaluation of SBPs among NRAs in line with
the currentWHO guidelines is critical. It is important to achieve the
goal of the guideline established byWHOwith an aim of promoting
global consensus on the regulation of SBPs to enhance the
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point of view, the speaker proposed two key needs for facilitating
the development of SBPs. The ﬁrst key need is the availability of
a reference standard for validating methods in quality assessment
of the SBPs. The second need is to establish product-class speciﬁc
guidance which deﬁne at least minimum requirements for plan-
ning the studies required for product development (e.g. EMA
guidelines for products such as insulin, growth hormone etc).
Dr Xu Chen (Beijing Tri-Prime Genetic Engineering Co., China)
presented an example of developing interferon eye drops for use in
treatment of herpes simplex keratitis. According to Provisions for
Drug Registration in China, this product belongs to biological
products in category 14 and 15 which are the products with
a change in route of administration (not including category 12) and
admitted with national standards. Preparation process (e.g. inocu-
lation, fermentation and puriﬁcation) and quality standard (e.g. the
biological activity, purity, molecular weight, mouse IgG residue)
were compared to evaluate the consistency between the product
under development and the marketed one (interferon for injec-
tion). Head-to-head comparison of these two products in clinical
trial was performed, but not required for quality part. In the context
of good consistency, clinical safety and effectiveness of the product,
toxicological study with only one animal species is generally
required and long-term toxicity testing may be shortened. If the
applicant provides evidence to conﬁrm a product’s consistency
with the reference product, they can also apply for exemption from
conducting pharmacology and toxicology studies.
7.1. Panel discussion
During the panel discussion, it became clear that the situation in
terms of SBPs and implementation of the WHO guidelines is very
diverse in different countries. Consequently, a harmonized
approach for SBPs worldwide is unlikely to occur rapidly. While
some countries have developed guidelines or are developing
guidelines, some countries are taking a relaxed view and are not
committed on the approach to adopt for approval for SBPs.
In some countries, guidelines have been developed which use
two approval pathways; the biosimilar route (same as WHO SBP)
and a highly divergent pathway. For example, Brazil explained the
basis of the alternative pathway for SBPs, a route that is being
followed by the country (simultaneously to the biosimilar
pathway). This avoids the comparison with the innovator product
and allows licensingwith abbreviated non-clinical and clinical data.
Concern was raised among the participants as this route is not
recommended in theWHO SBP and was speciﬁcally not included in
the approved guideline following considerable discussions. More-
over, approval by this process does not provide assurance that the
product has a similar beneﬁt to risk ratio as the reference product
although in some instances post-marketing commitment is
requested in an attempt to address this. The terminology for
deﬁning these products is also a matter of concern.
Some countries such as Thailand plan to develop guidelines
based on the WHO guidance within 1e2 years. Malaysia has
developed guidelines using the EMA concept but will harmonize
with WHO regarding acceptability of the RBP; no biosimilars have
been approved so far. Similarly, the Cuban approval procedure is
based on WHO guidance. Canada and Japan have adopted bio-
similar guidelines that are based on the same principles as EMA and
WHO Guidelines [15,16]. However, there are several requirements
that are more speciﬁc than the principles in WHO Guidelines. For
instance, labelling in the case of Japan, and intellectual property
issues in the case of Canada.
While it is clear that the main goal of India and China, which are
growing economies with large populations, is to increase patientaccess to these biomedicines, these countries have several manu-
facturers of these products who are targeting not only local but also
other territories. These countries are currently lagging behind in
terms of their regulations and need to act rapidly in developing
appropriate regulations/guidelines for product approval so the
locally manufactured products are comparable to the innovator
products in terms of their efﬁcacy and safety proﬁle.
Therewas general consensus that the terminology of ‘biosimilar’
products should reﬂect that the products are biosimilars based on
a comprehensive comparability exercise at the quality, non-clinical
and clinical level. Products not authorized by this comparability
regulatory pathway should not be called biosimilars. Labelling of
the product was also discussed. Japan has BS in the product name to
reﬂect that the product is a biosimilar but in other countries e.g. EU,
there is no identiﬁer in the name to indicate whether the product is
a biosimilar. If a product has no trade name, the INN followed by the
manufacturer name is used in the EU. For products that are not SBPs
however, the terminology and labelling is a challenge which needs
to be addressed.
During the closed session, the question of ‘SBPs prequaliﬁcation’
wasraised. It is clear that theexampleofvaccineprequaliﬁcationdoes
not apply to SBPs due to a number of differences in the use of these
products and public health interest. Moreover, none of the interna-
tional agencies expressedan intention toprocure SBPs contrary to the
situationwithUnitedNations Children’s Fund (UNICEF) and vaccines.
Therefore, different mechanisms need to be explored.
Another issue discussed in the closed session is related to the
applicability of clinical data generated in one ethnic group to
another. One problem with this is that certain ethnic groups will
have certain gene mutations and may be highly responsive to
therapy compared with other populations. For example in an
oncology setting, Iressa treatment induced a 6% response rate in
most populations, but a 34% response in Asian populations. The
genetic susceptibility and genomic proﬁle of patients are very
important in this respect. It was proposed to consult ICH Guidelines
E5 where this situation was speciﬁcally addressed (question 11) in
response to the request from Japan [17].
7.2. Main conclusions and way forward
1. WHO Guidelines on the evaluation of SBPs were recognized by
the workshop participants as a tool for harmonizing regulatory
requirements worldwide.
2. Representatives from National Regulatory Authorities from 10
countries reported that their national requirements are being
deﬁned on the basis of the principles outlined in WHO
Guidelines. However, variations in terms of the national
requirements for quality, safety and efﬁcacy of these products
revealed diversity in the regulatory expectations in different
countries and regions. It is important tomonitor progress at the
global level and WHO secretariat accepted to take a lead in
collecting and sharing the information on a regular basis.
3. Link between terminology and the regulatory evaluation is
critical. It was agreed that the products for which similarity to
an RBP, in terms of quality, non-clinical and clinical perfor-
mance, demonstrated through the full comparability study
should be named SBPs. However, lack of terminology for the
products developed as copy products (so called "me too"
products) with a partial comparability to an RBP, led to a great
diversity in evaluating as well as naming these products.
Revision of WHO Guidelines for assuring the quality of prod-
ucts prepared by recombinant DNA technology (WHO TRS 814)
is seen as an opportunity for elaborating on this point [18].
4. Concept of comparability studies is not used in developing
countries as it is the case in EU. In some countries in PAHO/
63%
6%
31%
NRA
Academic
Industry
Fig. 1. Participant afﬁliations.
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Guidelines and EMAGuidelines is not supported. Therefore, the
application of the principle for comparability to the RBP was
recognized as an issue that needs to be addressed in one of the
future implementation workshops.
5. Reference Biotherapeutic Product (RBP) is an issue where
regulatory requirements differ. Majority of the NRAs involved
in the discussion will accept RBP which is not licensed in their
country but is licensed and used in another country (so called
"foreign RBP"). However, two countries in addition to EU will
insist on the RBP licensed in their own country (Japan and
Singapore) [6,16].
6. Clinical evaluation of SBPs and related statistical analysis are
critical for regulatory decision. These two aspects are recog-
nized as weak points in the overall assessment of biological
products in general, and SBPs in particular. Lack of expertise in
reviewing clinical data is an issue that majority of NRAs are
struggling with. NRAs are encouraged to build capacity in
clinical trials review and statistical analysis.
7. Non-clinical evaluation of SBPs is an area where the principles
outlined in WHO Guidelines were well accepted by the regu-
lators and SBPmanufacturers. The experience in EU revealed an
evolving concept of non-clinical studies and a discrepancy
between the evaluation of products before EMA guidelines and
after.
8. Quality assessment of SBPs is the issue that the workshop
recognized as a key topic for the next implementation work-
shop. Comparability in terms of quality parameters is an issue
of great diversity in the national requirements. In some coun-
tries such as China, comparability in the quality aspect means
a comparison to the national standards (i.e. Pharmacopoeial). It
was agreed that a review article on the intended use of the
international reference preparations should be published as
a tool for information sharing. Another aspect that requires
further discussions is related to continuous and frequent
changes of the originator products. How to relate this issue in
demonstrating similarity to the reference product is perceived
as one of the most complex issues.
9. Labelling is an important issue for the use of SBPs. Majority of
countries reported that the indication of SBP in the label of the
product is not required. The exception is Japan where SBPs
should be distinguished from originators in the product label.
In Malaysia, this distinction has to be made in the package
insert but not in the product label. It is a common practice to
use trade name, company name and INN. Workshop partici-
pants recognized that the labelling approach for SBPs differ
from the generic products where the use of INN and a company
name without trade name is a common practice.
10. Information sharing among NRAs is a good practice that should
be promoted at the global level. One of the actions for NRAs is
to publish assessment reports on their web sites following the
example of EMA and Health Canada.
11. WHO should assist NRAs in building and improving technical
expertise in the evaluation of SBPs by providing some learning
tools as well as opportunities for information and knowledge
sharing. In line with this, it was agreed to publish outcomes of
this workshop in a peer-reviewed scientiﬁc journal and to
prepare Questions and Answers for WHO biologicals web site.
12. Key messages for ICDRA meeting are: a) NRAs should take an
active role in building capacity for regulatory evaluation of
biotherapeutics; b) the workshop participants required revi-
sion of WHO Guidelines for assuring the quality of products
prepared by recombinant DNA technology (WHO TRS 814); and
c) WHO should continue monitoring progress with the
implementation of the Guidelines on the evaluation of SBPsinto regulatory and manufacturers’ practices and provide
information on a regular basis.
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is very much appreciated.Annex. Assessment of questionnaire responses to evaluate
the workshop
The objectives of the questionnaire were:
1. To survey participant satisfaction in the workshop
2. To identify the areas proposed for planning future workshops
3. To identify current gaps and additional needs in implementing
the WHO Guidelines
4. To identify further needs of WHO assistance to improve the
system in countries
With the exception of WHO staff, a total of 38 experts from 13
different countries, i.e. Brazil, Canada, People’s Republic of China
(China), Cuba, India, Iran, Japan, Jordan, Republic of Korea (Korea),
Malaysia, Singapore, Thailand, and United Kingdom of Great Britain
and Northern Ireland (UK) attended the Workshop. 32/38 partici-
pants (84%) returned the questionnaire. Most participants (63%)
were regulatory authorities, and some experts were from the
industries (31%) and from academia (6%) (Fig. 1).
I. The summary of responses about the Workshop as follows:
1. 29/32 (91%) responders considered that the Workshop was the
right length (Fig. 2).
2. 25/32 (78%) responders considered that the Workshop was
timely balanced between presentations and discussion (Fig. 3).
3. Responders considered the following points for the most
informative sections in the Workshop (included multiple
responses) (Fig. 4).
a. Updating region/country situations (56%)
6%
78%
13%
3%
less discussion
all right
more discussion
no response
Fig. 3. Satisfaction of time balance between presentations and discussion (total 7 h
discussion was stopped by chair at the end of each presentation) (n ¼ 32 responders).
6%
91%
3%
too short
all right
too long
Fig. 2. Satisfaction of length of workshop (n ¼ 32 responders).
Fig. 4. Informative sessions of the Workshop (n ¼ 32 r
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simulated case studies (53%)
c. Better understanding of principles of clinical evaluations,
i.e. lecture and reviewing practical examples (34%)
d. Sharing experiences of comparability studies andRBPs (19%)
e. Manufacturers’ perspectives on implementation of WHO
Guidelines (13%)
f. Challenges raised by reviewers (9%)
g. Introduction (6%)
4. Additional written proposals (20 responders) for the future
workshops were (included multiple responses) (Fig. 5):
a. Include topics for quality issues, e.g. comparability study,
international standards (45%)
b. Include more case studies (20%)
c. Invite more inﬂuential people, e.g. regulatory authorities
from USA and India, and director of authorities (15%)
d. Include more information about clinical design and
analysis (10%)
e. Include the topic for risk management plan (10%)
f. Others: include the topics for rDNA products in general,
interchangeability, immunogenecity.
II. The summary of responses about implementing the WHO
Guidelines as follows:
1. 9/13 (69%) countries indicated that the main principles of the
WHO Guidelines could be applicable to their national regula-
tions (Fig. 6).
2. 4/13 (31%) countries indicated that the following points of the
WHO Guidelines could not be applicable to their national
regulation:
a. China: head-to-head comparability exercise in clinical trial
b. Cuba: head-to-head comparative clinical study for appli-
cation of monoclonal antibody products
c. India: equivalence study in clinical trial because of demand
for great expense of RBPs
d. Iran: equivalence study in clinical trial because of requiring
large number of sample sizeesponders; Feedback includes multiple responses).
15
15
45
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20
10
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Others (e.g. include topics for rDNA products in
general, interchangeability, immunogenecity)
Invite more influential people (e.g. NRAs from
USA and India, head of NRAs)
Include topics for quality issues (e.g.
comparability study, international standards)
Include more information about clinical design
and analysis
Include more case study 
Include topics for risk management plan
%
Fig. 5. Proposal for the topics of future workshops (n ¼ 20 responders; Feedback includes multiple responses).
Fig. 6. Applicability of implementing WHO Guidelines into the national regulation
(n ¼ 13 countries).
M. Wadhwa et al. / Biologicals 39 (2011) 349e3573563. Proposals (26 responders) for additional information to be
included in the Guidelines were (included multiple responses)
(Fig. 7):
a. Include product speciﬁc and more detail guidelines (46%)
b. Include INN issues (12%)0
no needs
INN
PhV
product specific guidelines
Others (e.g. Q&A, alternative pathway, advanced
methodology, labeling, interchangeability, etc)
%
Fig. 7. . Proposal for additional information to be included in the Guidc. Include topics for PMS and PhV plan for the speciﬁc of
SBPs (8%)
d. Others: include Q&A, alternative pathway, advanced
methodology in clinical evaluation, labelling issues, inter-
changeability, etc (23%)
e. No needs (31%)
III. The summary of responses about further needs of WHO
assistance to improve the system in countries (n ¼ 13 countries;
Feedback includes multiple responses) (Fig. 8)
1. 8/13 (62%) countries indicated that training including
workshops in their countries was necessary assistance from
WHO
2. 3/13 (23%) countries indicated the needs of exchanging expe-
rience among NRAs
3. 2/13 (15%) countries suggested arranging a meeting with the
heads of their national regulatory authorities to motivate them
4. 2/13 (15%) countries indicated the needs of revision of rDNA
product guidelines in general
5. Others: help to get RBPs, prequaliﬁed SBPs by WHO31
12
8
46
23
5 10 15 20 25 30 35 40 45 50
elines (n ¼ 26 responders; Feedback includes multiple responses).
Fig. 8. Further need of WHO assistances to improve the system in countries.
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